Fosun International Ltd held its position in shares of BeyondSpring Inc. (NASDAQ:BYSI) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 240,000 shares of the company’s stock at the end of the 2nd quarter. BeyondSpring makes up 1.3% of Fosun International Ltd’s portfolio, making the stock its 16th largest holding. Fosun International Ltd owned about 1.11% of BeyondSpring worth $10,291,000 at the end of the most recent quarter.
BYSI has been the subject of several analyst reports. HC Wainwright set a $43.00 price target on shares of BeyondSpring and gave the company a “buy” rating in a research report on Wednesday, May 31st. Maxim Group initiated coverage on shares of BeyondSpring in a research report on Tuesday, August 22nd. They set a “buy” rating and a $52.00 price target for the company. Zacks Investment Research lowered shares of BeyondSpring from a “hold” rating to a “sell” rating in a research report on Monday, July 3rd. Finally, Rodman & Renshaw upped their price target on shares of BeyondSpring from $43.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, July 14th.
BeyondSpring Inc. (BYSI) traded up 1.20% during mid-day trading on Friday, reaching $38.00. 2,545 shares of the company’s stock traded hands. BeyondSpring Inc. has a one year low of $16.55 and a one year high of $48.49. The firm’s 50-day moving average price is $38.58 and its 200 day moving average price is $32.25. The firm’s market cap is $868.07 million.
TRADEMARK VIOLATION WARNING: This news story was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://transcriptdaily.com/2017/09/17/beyondspring-inc-bysi-stake-held-by-fosun-international-ltd.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.